Cramer recommended Sirna Therapeutics Inc (RNAI) three weeks ago and on Monday Sirna announced a deal with GlaxoSmithKline Plc (GSK). Cramer had the CEO of Sirna Therapeutics Inc on the show tonight to talk about the deal and the prospects of the company. Robin said the deal would not only improve efforts to treat asthma and chronic pulmonary disease by pairing Sirna's technology with GlaxoSmithKline treatments, but also it would mean significant royalties and milestone payments for his company. Robin also informed investors that the payments will be made out over time as drugs are approved in the future. Robin also thinks the market for asthma drugs is growing fast but his company is positioned to treat a diverse range of treatments besides asthma.
